French drugmaker Sanofi is buying the rights to seek approval for a version of the erectile dysfunction drug Cialis that customers would be able to buy without a doctor's prescription.
May 28, 2014
0
0
The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
Mar 31, 2014
0
0
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.
Dec 17, 2013
0
0
The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...
Dec 11, 2013
0
0
(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said Friday.
Nov 8, 2013
0
0
Researchers at Washington University School of Medicine in St. Louis are studying the quality, effectiveness and safety of generic drugs used to treat depression.
Nov 4, 2013
0
0
(Medical Xpress)—People given a choice between generic or branded drugs should look closely at the ingredients in the drug they are buying, argue economists from Deakin University's Graduate School of Business.
Sep 16, 2013
0
0
Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...
Jul 30, 2013
0
0
A free trade pact being negotiated by the U.S. and 11 Asia-Pacific nations will impose aggressive intellectual property rules that could restrict access to affordable medicines in developing nations, health activists warned ...
Jul 3, 2013
0
0
(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives to a ...
Jun 19, 2013
0
0
